# RET in thyroid cancer

3 EU-approved indications in thyroid cancer need a RET result: vandetanib (advanced), selpercatinib (advanced) and selpercatinib (advanced).

## Approved indications

### RET

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Selpercatinib](https://oncolabels.com/drugs/selpercatinib) (Retsevmo) | RET fusion | Monotherapy | Advanced | Radioactive iodine-refractory (if radioactive iodine is appropriate); aged 2 years and older |
| [Selpercatinib](https://oncolabels.com/drugs/selpercatinib) (Retsevmo) | RET mutation | Monotherapy | Advanced | Medullary thyroid cancer only; Aged 2 years and older |
| [Vandetanib](https://oncolabels.com/drugs/vandetanib) (Caprelsa) | RET mutation | Monotherapy | Advanced | Medullary thyroid cancer only; Aggressive and symptomatic disease; aged 5 years and older |

## Tumour-agnostic approvals

Approved for any solid tumour that carries the alteration, wherever the tumour started.

### RET fusion

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Selpercatinib](https://oncolabels.com/drugs/selpercatinib) (Retsevmo) | RET fusion | Monotherapy | Advanced | Treatment options not targeting RET provide limited clinical benefit, or have been exhausted; Aged 2 years and older |

## Label wording

- **Vandetanib** (Caprelsa), Thyroid cancer, advanced: “Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf)
- **Selpercatinib** (Retsevmo), Thyroid cancer, advanced: “advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf)
- **Selpercatinib** (Retsevmo), Thyroid cancer, advanced: “advanced RET-mutant medullary thyroid cancer (MTC).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/thyroid-cancer/ret